Angelalign Technology Inc. 2025 Annual Report: Key Takeaways for Investors

Robust Financial Performance and Significant Profit Growth

• Revenue Surge: Angelalign Technology Inc. reported a remarkable 37.7% year-on-year increase in revenue, reaching USD 370.3 million for the year ended December 31, 2025, up from USD 268.8 million in 2024.
• Gross Profit: Gross profit soared to USD 232.9 million, representing a robust gross profit margin of 62.9%, up slightly from 62.6% in the prior year. This indicates strong pricing power and effective cost management.
• Net Profit Jump: Net profit attributable to owners of the Company surged by 163% to USD 28.4 million compared to USD 12.1 million in 2024. The net profit margin improved significantly from 3.7% to 7.1%.
• Adjusted Net Profit: On a non-IFRS basis, adjusted net profit rose by 63% to USD 43.8 million, with an adjusted net profit margin of 11.8% (up from 10.0%). This metric strips out share-based payments, certain fair value losses, and foreign exchange impacts, offering a clearer view of business performance.

Dividend Announcements: Strong Shareholder Returns

• Final and Special Dividends: The Board has recommended a final dividend of HKD 0.48 per share and an extraordinary special dividend of HKD 4.99 per share, both subject to shareholder approval at the AGM. These payouts demonstrate management’s confidence in the business and commitment to returning value to shareholders.
• Payout Policy: Angelalign targets a payout ratio of approximately 40% of net profit attributable to shareholders, subject to financial performance, capital requirements, and future development plans.

Business Highlights: Market Position and Growth Initiatives

• Chinese Mainland Market: The adjusted segment profit in the Chinese mainland market grew to USD 51.3 million, up from USD 36.6 million, reflecting continued revenue growth and economies of scale.
• Operational Leverage: The improved profitability was supported by revenue expansion, operational leverage from global infrastructure, and timing of certain operating and legal expenses.
• Employee Strength: The company employed 4,312 staff as of end-2025, with total staff costs (including share-based payments) at USD 166.6 million, reflecting investment in talent and growth.
• Manufacturing and Facilities: As of year-end, Angelalign owned one land parcel (68,883.3 sqm), operated 6 owned and 27 leased properties, and continued its focus on global production and R&D expansion.

Balance Sheet Strength and Liquidity

• Strong Liquidity: The current ratio was 3.0, indicating healthy liquidity for ongoing operations and investments.
• Distributable Reserves: The company’s reserves available for distribution to shareholders stood at USD 397.2 million as of December 31, 2025, providing ample flexibility for dividends and strategic investments.
• No New Debentures: No debentures were issued during the reporting period, and the company maintained a solid capital structure.

Share Award Schemes and Capital Structure

• Equity Incentives: The company operates Pre-IPO and Post-IPO share award and option schemes to retain and motivate key talent.
• Maximum Share Option Pool: As of December 31, 2025, up to 10,145,867 shares (5.94% of issued shares) were available for option grants, with 4,820,036 shares available for future grants.
• No Share Repurchases: The company did not purchase, sell, or redeem any of its listed securities during 2025, nor did it hold any treasury shares at year-end.

Related Party and Connected Transactions

• Investment in Shanghai Maxflex: In August 2025, Angelalign (through Wuxi EA) invested RMB 10 million to acquire a 5% stake in Shanghai Maxflex, a connected entity controlled by CareCapital Group, raising its total interest in Maxflex to 9.7%. This was a connected transaction under HKEX rules.
• Continuing Connected Transactions: The company’s continuing connected transactions, including purchases and sales with related parties, were reviewed by the auditor and found in compliance with the Listing Rules. No annual caps were exceeded, and internal controls were deemed effective.

Corporate Governance, Risk, and ESG Practices

• Governance: Angelalign maintained high standards of corporate governance, with full compliance with the HKEX Corporate Governance Code. The Board, Audit, Nomination, and Remuneration Committees actively oversaw strategy, risk, and remuneration matters.
• Risk Management: The Board and management regularly monitor key market, credit, and liquidity risks. Internal audit and control systems were reviewed and found effective.
• ESG Compliance: The company reported full compliance with environmental, social, and occupational health and safety laws in China and other operating countries. No material non-compliance incidents or environmental claims occurred in 2025.

Shareholding Structure and Public Float

• Major Shareholders: CareCapital Group and related entities held a combined 51.04% of the company’s shares, with Ms. LI Huamin and associates controlling an additional 12.39%. JPMorgan Chase & Co. held 11.21%.
• Public Float: As of December 31, 2025, the public float was 21.64%, above the minimum required by the HKEX waiver.

Other Noteworthy Items

• Use of IPO Proceeds: Of the HKD 3,139 million raised in the 2021 IPO, substantial amounts have been deployed toward the Chuangmei Center, R&D, and business expansion, with HKD 583.8 million remaining unutilized as at year-end 2025.
• Future Outlook: The company acknowledges market risks from economic uncertainty and evolving regulations. Detailed business outlook is provided in the MD&A and Outlook sections of the report.
• No Material Litigation: The Group did not experience any material litigation or non-compliance events likely to adversely impact business or financial condition in 2025.
• Upcoming AGM: The Annual General Meeting is scheduled for May 19, 2026, where approval for the dividend and amendments to the Articles of Association will be sought.

Potential Share Price Sensitivities

• Significant Dividend Declaration: The large special dividend (HKD 4.99 per share) is a notable return of capital and may attract investor attention and affect the share price upon approval and payment.
• Strong Profit Growth: The robust growth in both net and adjusted profits may lead to positive re-rating of the stock.
• Strategic Investments: The investment in Shanghai Maxflex and ongoing expansion in manufacturing and R&D signal continued growth ambitions.
• Compliance and Governance: No material non-compliance or litigation risks, plus strong internal controls, may reassure investors regarding operational risks.

Disclaimer

The information provided above is a summary and analysis based on Angelalign Technology Inc.’s 2025 Annual Report. This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors are advised to conduct their own due diligence and consult with their financial advisor before making investment decisions. The company’s future performance is subject to risks, market conditions, and other uncertainties.

View ANGELALIGN Historical chart here